Phillip E. Lee's most recent trade in Vaxart Inc was a trade of 610,000 Stock Option (right to buy) done . Disclosure was reported to the exchange on March 24, 2025.
Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
---|---|---|---|---|---|---|---|---|---|---|
Vaxart Inc | Phillip E. Lee | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Mar 2025 | 610,000 | 610,000 | - | - | Stock Option (right to buy) | |
Vaxart Inc | Phillip E. Lee | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Mar 2025 | 406,000 | 631,619 (1%) | 0% | 0 | Common Stock | |
Vaxart Inc | Phillip E. Lee | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.57 per share. | 18 Mar 2025 | 8,050 | 225,619 (0%) | 0% | 0.6 | 4,590 | Common Stock |
Vaxart Inc | Phillip E. Lee | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.59 per share. | 15 Dec 2024 | 6,132 | 233,669 (0%) | 0% | 0.6 | 3,630 | Common Stock |
Vaxart Inc | Phillip E. Lee | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.76 per share. | 12 Jun 2024 | 2,007 | 239,801 (0%) | 0% | 0.8 | 1,525 | Common Stock |
Vaxart Inc | Phillip E. Lee | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Dec 2023 | 410,000 | 410,000 | - | - | Stock Option (right to buy) | |
Vaxart Inc | Phillip E. Lee | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Dec 2023 | 90,000 | 241,808 (0%) | 0% | 0 | Common Stock | |
Vaxart Inc | Phillip E. Lee | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.71 per share. | 08 Dec 2023 | 35,151 | 157,751 (0%) | 0% | 0.7 | 24,957 | Common Stock |
Vaxart Inc | Phillip E. Lee | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.63 per share. | 08 Dec 2023 | 5,943 | 151,808 (0%) | 0% | 0.6 | 3,744 | Common Stock |
Vaxart Inc | Phillip E. Lee | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2023 | 102,500 | 102,500 | - | - | Stock Option (right to buy) | |
Vaxart Inc | Phillip E. Lee | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2023 | 22,500 | 192,902 (0%) | 0% | 0 | Common Stock | |
Vaxart Inc | Phillip E. Lee | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Mar 2023 | 205,000 | 205,000 | - | - | Stock Option (right to buy) | |
Vaxart Inc | Phillip E. Lee | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Mar 2023 | 56,652 | 170,402 (0%) | 0% | 0 | Common Stock | |
Vaxart Inc | Phillip E. Lee | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Mar 2023 | 45,000 | 113,750 (0%) | 0% | 0 | Common Stock |